Baxter Discontinues Use Of Advate Sales Aids Cited In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
CBER takes issue with display of adverse event information and supporting data for statements made in the brochures. FDA says Advate warning letter is unrelated to one issued two weeks earlier for Baxter’s IgIV product Polygam S/D.